Chemomab Therapeutics (CMMB) Accumulated Depreciation (2020 - 2021)
Chemomab Therapeutics' (CMMB) quarterly Accumulated Depreciation came in at $107000.0 in Q4 2021, up 46.58% on a YoY basis from $73000.0 in Q4 2020, and up 46.58% quarter-over-quarter from $73000.0 in Q4 2020.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Accumulated Depreciation (2020 - 2021) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Accumulated Depreciation for 2 consecutive years, with $107000.0 the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Accumulated Depreciation rose 46.58% year-over-year to $107000.0; the trailing twelve-month figure through Dec 2021 stood at $107000.0 (up 46.58% YoY), and the FY2021 full-year result was $107000.0, up 46.58% from the prior year.
- Accumulated Depreciation improved to $107000.0 in Q4 2021 per CMMB's latest filing, from $73000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $107000.0 in Q4 2021 and bottomed at $73000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Chemomab Therapeutics | 19.49 Mn | 19.49 Mn | - |